Stephen H. Leppla, Ph.D.Building 33, Room 1W20B.733 North DriveBethesda, MD 20892-3202 Phone: 301-594-2865Fax: firstname.lastname@example.org
Chief, Microbial Pathogenesis Section, LPD
The Microbial Pathogenesis Section studies bacterial diseases related to biodefense pathogens. Research focuses on identification and analysis of bacterial virulence factors and their genetic regulation; structure-function analysis of bacterial proteins and other factors; disease pathogenesis; and development of diagnostics, vaccines, and therapeutics.
Dr. Leppla earned a B.S. in biology from the California Institute of Technology and a Ph.D. in biochemistry from the University of Wisconsin. After postdoctoral study at the University of California-Berkeley and Brown University, he became a research scientist at the U.S. Army Medical Research Institute of Infectious Diseases in Frederick, Maryland. He moved to the National Institutes of Health in 1989 and to NIAID in 2003.
Shihui Liu, Staff ScientistMahtab Moayeri, Staff Scientist (Core)Andrei Pomerantsev, Staff Scientist (Core)Mini Varughese, Scientific Operations ManagerMyriam Megouache, Lab SecretaryChristopher Bachran, Visiting FellowInka Sastalla, Research FellowClinton Leysath, Postdoctoral IRTAKuang Hua Chen, MicrobiologistRasem Fattah, ChemistDevorah Crown, ContractorYi Zhang, ContractorAllyse Hellmich, Postbaccalaureate IRTAAlex Wein, Postbaccalaureate IRTASuzanne Abdelazim, Student IRTAAndrew McKenzie, Postbaccalaureate IRTADami Phillips, Postbaccalaureate IRTA
back to top
Cirelli KM, Gorfu G, Hassan MA, Printz M, Crown D, Leppla SH, Grigg ME, Saeij JP, Moayeri M. Inflammasome sensor NLRP1 controls rat macrophage susceptibility to Toxoplasma gondii. PLoS Pathog. 2014 Mar;10(3):e1003927.McKenzie AT, Pomerantsev AP, Sastalla I, Martens C, Ricklefs SM, Virtaneva K, Anzick S, Porcella SF, Leppla SH. Transcriptome analysis identifies Bacillus anthracis genes that respond to CO2 through an AtxA-dependent mechanism. BMC Genomics. 2014;15(1):229.Leysath CE, Phillips DD, Crown D, Fattah RJ, Moayeri M, Leppla SH. Anthrax edema factor toxicity is strongly mediated by the N-end rule. PLoS One. 2013; 8(8):e74474.Liu S, Zhang Y, Moayeri M, Liu J, Crown D, Fattah RJ, Wein AN, Yu ZX, Finkel T, Leppla SH. Key tissue targets responsible for anthrax-toxin-induced lethality. Nature. 2013 Sep;501(7465):63-68.Phillips DD, Fattah RJ, Crown D, Zhang Y, Liu S, Moayeri M, Fischer ER, Hansen BT, Ghirlando R, Nestorovich EM, Wein AN, Simons L, Leppla SH, Leysath CE. Engineering anthrax toxin variants that exclusively form octamers, and their application to targeting tumors. J Biol Chem. 2013 Feb;288(13):9058-9065.Levinsohn JL, Newman ZL, Hellmich KA, Fattah R, Getz MA, Liu S, Sastalla I, Leppla SH, Moayeri M. Anthrax lethal factor cleavage of Nlrp1 is required for activation of the inflammasome. PLoS Pathog. 2012 Mar;8(3):e1002638.Visit PubMed for a complete publication list.
Leppla SH, Schneerson R, Robbins JB, inventors; United States of America as represented by the Secretary of the Department of Health and Human Services, assignee. Methods of using Bacillus anthracis protective antigen sequences for vaccination. United States patent 8,703,150. 22 Apr 2014.
Chen Z, Leppla SH, Moayeri M, Emerson SU, Purcell RH, inventors; United States of America as represented by the Secretary of the Department of Health and Human Services, assignee. Monoclonal antibodies that neutralize anthrax protective antigen (PA) toxin. United States patent 8,685,396. 1 April 2014.
Schneerson R, Kubler-Kielb J, Majadly F, Leppla SH, Robbins JB, Liu DT, Shiloach J, inventors; United States of America as represented by the Secretary of the Department of Health and Human Services, assignee. Methods for preparing immunogenic conjugates. United States patent 8,481,048. 9 Jul 2013.
Leppla SH, Rosovitz MJ, Robbins JB, Schneerson R, Hsu D, Shiloach J, Ramirez DM, inventors; United States of America as represented by the Secretary of the Department of Health and Human Services, assignee. Recombinant modified Bacillus anthracis protective antigen for use in vaccines. United States patent 8,394,387. 12 Mar 2013.
Leppla SH, Liu SH, Bugge TH, inventors; United States of America as represented by the Secretary of the Department of Health and Human Services, assignee. Multimeric protein toxins to target cells having multiple identifying characteristics. United States patent 8,388,933. 5 Mar 2013.
Visit the U.S. Patent and Trademark Office for a complete list of patents.
Last Updated June 26, 2014